Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management (LDL-ALERT)
Hyperlipemia, Mixed, ASCVD
About this trial
This is an interventional treatment trial for Hyperlipemia, Mixed focused on measuring hyperlipidemia, cholesterol, lipid-lowering, decision support
Eligibility Criteria
Inclusion:
- patients ≥ 18 years old AND
- admitted to the BWH Cardiovascular Medicine Service with a diagnosis (primary or secondary), medical history entry, or problem list entry of ASCVD (acute coronary syndromes, a history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease) AND
- most recent (within 1 year) or current LDL-C value greater than 80 mg/dL AND
- on a statin but not on ezetimibe and/or PCSK9 inhibitor will be potentially eligible for randomization
Exclusion:
-already receiving PCSK9 inhibitor therapy
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Alert
No Alert
an on-screen electronic alert will prompt the responsible inpatient provider (inpatient cohort) or the cardiologist of record for the clinic visit (outpatient cohort) as follows: All patients whose LDL-C is not less than 70 mg/dL and not taking a maximally tolerated statin dose will prompt a recommendation for statin intensification All patients whose LDL-C is within 20% of 70 mg/dL and who are on a maximally tolerated statin dose but not on ezetimibe or PCSK9 inhibitor will receive a prompt for adding ezetimibe All patients whose LDL-C is greater than 20% of goal, and on a maximally tolerated statin (±ezetimibe) but not on PCSK9 inhibitor will receive a prompt for initiating PCSK9 inhibitor
No notification will be issues